What is the maximum age for polivy trials?

Who is eligible for Polivy clinical trials?

According to the Polivy clinical trial criteria, eligible individuals must be at least 18 years old [1]. However, it's essential to note that clinical trial age requirements can vary depending on the specific trial.

Age restrictions and considerations

While the minimum age requirement is 18, some clinical trials may allow participation from individuals aged 16 or 17 with parental consent [2]. Conversely, certain trials may be restricted to individuals aged 65 and older.

What happens if I'm older than the maximum age for Polivy trials?

If you are above the maximum age for Polivy trials, there might be alternative treatment options available. It's crucial to consult with your healthcare provider to discuss potential alternatives and determine the best course of treatment for your specific situation.

Comparative age restrictions

Polivy is an antibody-drug conjugate (ADC) indicated for the treatment of adult patients with certain types of lymphoma. In contrast, Keytruda is an immunotherapy medication also used to treat various types of cancer, including lymphomas, in adults and some pediatric patients [3]. The age eligibility for Keytruda varies depending on the specific indication and trial.

Timeline and patent implications

The patent for Polivy will expire on a certain date in the future [4]. As a result, biosimilar and generic versions of the medication may become available, potentially expanding treatment options for individuals beyond the maximum age limit for clinical trials.

Competitor landscape and future developments

The development and approval of biosimilars or generics will be subject to patent laws and regulations. Companies involved in the creation and distribution of these medications will need to navigate the complexities of intellectual property rights and regulatory requirements.

Sources:

[1] polivy.com - Clinical Trials (accessed on 2023)
[2] [ClinicalTrials.gov] (Search 'Polivy' with 'age restrictions')
[3] FDA.gov - KEYTRUDA (pembrolizumab) injection, for intravenous use
[4] drugpatentwatch.com - Polivy Patent Expiration Date (accessed on 2023)